Immune to Cancer: The CRI Blog
-
5 Things Patients, Caregivers, and Families Need to Know About Cancer
Our CEO speaks with Medium/Authority Magazine about cancer, immunotherapy, and how she became CEO of the world’s… -
AACR 2022 Recap: T Cells Still On Top, But Make Room for Myeloid Cells
At the 2022 AACR annual meeting, CRI scientists highlighted a wide scope of cancer immunology advances, and…
-
FDA Approves New LAG-3 Checkpoint Inhibitor Immunotherapy Combination
Patients with unresectable or metastatic melanoma can now be treated with dual checkpoint blockade targeting the PD-1…
-
Overcoming Immune Dysfunction in Brain Cancer with CRI Lloyd J. Old STAR Peter Fecci
CRI Arash Ferdowsi Lloyd J. Old STAR Peter Fecci is seeking to characterize and develop ways to…
-
Sarcoma Awareness Month: Tackling Chordoma with Dr. Cassian Yee
CRI-Chordoma Foundation CLIP Investigator Dr. Cassian Yee is exploring how to design cell therapies for patients with…
-
ASCO21 Recap: Immunotherapy’s Continued Progress and Addressing Healthcare Disparities
ASCO21 highlighted the latest immunotherapy advances in checkpoint inhibition and cell therapies, and addressed disparities in healthcare.
-
How Immunotherapy is Making an Impact in Gynecologic Cancers
For Gynecologic Cancer Awareness Month, CRI spoke with Dr. Kunle Odunsi about immunotherapies for ovarian, cervical, and…
-
Recapping ASCO20: The Next Horizons in Immunotherapy
The 56th Annual ASCO Meeting highlighted advances in checkpoint immunotherapy, cell-based immunotherapies, and bispecific antibodies.
-
ASCO20 Update: Considerations for Checkpoint Inhibitors Moving Forward
Results unveiled at ASCO20 increased our understanding of checkpoint immunotherapy in a variety of cancers and circumstances.